Alector, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Alector reported Q2 2026 results with cash/equivalents/investments of $172.8M (down from $256.0M at Dec 31, 2025), providing runway through 2027. Lead program AL137 (anti-amyloid-beta antibody) completed IND-enabling studies; company targets IND submission Q1 2027 and first-in-human dosing in Australia by April 2027. Net loss was $23.0M ($0.21/share) for Q2 2026 vs. $30.5M ($0.30/share) in Q2 2025; collaboration revenue declined to $3.3M (from $7.9M YoY) due to lower AL101 AD program revenue.
Why this rating
Cash burn (~$83M in 6 months) against $172.8M remaining is meaningful but runway extends to 2027. IND submission timing is material clinical milestone but routine for biotech. Stockholders' equity turned negative ($-9.97M), raising capital concern. Relative to $115M market cap, cash position is substantial but declining.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.